<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Igc Pharma, Inc. — News on 6ix</title>
<link>https://6ix.com/company/igc-pharma-inc</link>
<description>Latest news and press releases for Igc Pharma, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/igc-pharma-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d75dbe51cc36e475338d0a.webp</url>
<title>Igc Pharma, Inc.</title>
<link>https://6ix.com/company/igc-pharma-inc</link>
</image>
<item>
<title>IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion</title>
<link>https://6ix.com/company/igc-pharma-inc/news/igc-pharma-adds-kerwin-medical-center-in-dallas-to-phase-2-calma-trial-as-enrollment-advances-toward-completion</link>
<guid isPermaLink="true">https://6ix.com/company/igc-pharma-inc/news/igc-pharma-adds-kerwin-medical-center-in-dallas-to-phase-2-calma-trial-as-enrollment-advances-toward-completion</guid>
<pubDate>Wed, 22 Apr 2026 12:30:00 GMT</pubDate>
<description>Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation study POTOMAC, MD / ACCESS Newswire / April 22, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage ...</description>
</item>
<item>
<title>IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia</title>
<link>https://6ix.com/company/igc-pharma-inc/news/igc-pharma-secures-psilocybin-research-authorization-expanding-focus-on-neuropsychiatric-symptoms-in-dementia</link>
<guid isPermaLink="true">https://6ix.com/company/igc-pharma-inc/news/igc-pharma-secures-psilocybin-research-authorization-expanding-focus-on-neuropsychiatric-symptoms-in-dementia</guid>
<pubDate>Mon, 20 Apr 2026 12:30:00 GMT</pubDate>
<description>Authorization provides regulated capability to evaluate emerging therapeutic approaches alongside Phase 2 CALMA trial approaching completion POTOMAC, MD / ACCESS Newswire / April 20, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), ...</description>
</item>
<item>
<title>IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout</title>
<link>https://6ix.com/company/igc-pharma-inc/news/igc-pharma-reaches-80percent-enrollment-in-phase-2-calma-trial-entering-final-phase-ahead-of-enrollment-completion-and-data-readout</link>
<guid isPermaLink="true">https://6ix.com/company/igc-pharma-inc/news/igc-pharma-reaches-80percent-enrollment-in-phase-2-calma-trial-entering-final-phase-ahead-of-enrollment-completion-and-data-readout</guid>
<pubDate>Tue, 14 Apr 2026 12:30:00 GMT</pubDate>
<description>POTOMAC, MD / ACCESS Newswire / April 14, 2026 /IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated ...</description>
</item>
<item>
<title>Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts</title>
<link>https://6ix.com/company/igc-pharma-inc/news/ascendiant-capital-markets-raises-igc-pharma-price-target-to-dollar525-citing-clinical-progress-and-upcoming-catalysts</link>
<guid isPermaLink="true">https://6ix.com/company/igc-pharma-inc/news/ascendiant-capital-markets-raises-igc-pharma-price-target-to-dollar525-citing-clinical-progress-and-upcoming-catalysts</guid>
<pubDate>Wed, 08 Apr 2026 16:45:00 GMT</pubDate>
<description>POTOMAC, MD / ACCESS Newswire / April 8, 2026 /IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company with its lead program currently in a Phase 2 CALMA clinical trial evaluating IGC-AD1 for Alzheimer's-related ...</description>
</item>
<item>
<title>IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease</title>
<link>https://6ix.com/company/igc-pharma-inc/news/igc-pharma-adds-tandem-clinical-research-to-the-calma-trial-for-agitation-in-alzheimers-disease</link>
<guid isPermaLink="true">https://6ix.com/company/igc-pharma-inc/news/igc-pharma-adds-tandem-clinical-research-to-the-calma-trial-for-agitation-in-alzheimers-disease</guid>
<pubDate>Tue, 07 Apr 2026 12:00:00 GMT</pubDate>
<description>POTOMAC, MD / ACCESS Newswire / April 7, 2026 /IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing innovative treatments for Alzheimer's disease, today announced the activation of a new ...</description>
</item>
<item>
<title>IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness</title>
<link>https://6ix.com/company/igc-pharma-inc/news/igc-pharma-launches-strategic-national-media-partnership-with-new-to-the-street-to-expand-investor-awareness</link>
<guid isPermaLink="true">https://6ix.com/company/igc-pharma-inc/news/igc-pharma-launches-strategic-national-media-partnership-with-new-to-the-street-to-expand-investor-awareness</guid>
<pubDate>Mon, 30 Mar 2026 12:00:00 GMT</pubDate>
<description>POTOMAC, MD / ACCESS Newswire / March 30, 2026 /IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced a strategic 12-part national media ...</description>
</item>
<item>
<title>New to The Street and IGC Pharma (NYSE American:IGC) Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market Positioning</title>
<link>https://6ix.com/company/igc-pharma-inc/news/new-to-the-street-and-igc-pharma-nyse-americanigc-launch-strategic-12-part-national-media-partnership-to-accelerate-investor-awareness-and-market-positioning</link>
<guid isPermaLink="true">https://6ix.com/company/igc-pharma-inc/news/new-to-the-street-and-igc-pharma-nyse-americanigc-launch-strategic-12-part-national-media-partnership-to-accelerate-investor-awareness-and-market-positioning</guid>
<pubDate>Wed, 25 Mar 2026 12:00:00 GMT</pubDate>
<description>NEW YORK, NY / ACCESS Newswire / March 25, 2026 / New to The Street, a premier financial media platform known for its national television distribution and integrated investor engagement strategy, today announced a strategic 12-part media partnership ...</description>
</item>
<item>
<title>IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025</title>
<link>https://6ix.com/company/igc-pharma-inc/news/igc-pharma-reports-financial-results-and-clinical-progress-for-the-period-ended-december-31-2025</link>
<guid isPermaLink="true">https://6ix.com/company/igc-pharma-inc/news/igc-pharma-reports-financial-results-and-clinical-progress-for-the-period-ended-december-31-2025</guid>
<pubDate>Thu, 19 Mar 2026 13:00:00 GMT</pubDate>
<description>- Strategic Pivot to Pure-Play Biotech - POTOMAC, MD / ACCESS Newswire / March 19, 2026 /IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced ...</description>
</item>
<item>
<title>IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026</title>
<link>https://6ix.com/company/igc-pharma-inc/news/igc-pharma-to-showcase-ai-platform-with-alzheimers-disease-data-initiative-at-adpd-2026</link>
<guid isPermaLink="true">https://6ix.com/company/igc-pharma-inc/news/igc-pharma-to-showcase-ai-platform-with-alzheimers-disease-data-initiative-at-adpd-2026</guid>
<pubDate>Wed, 18 Mar 2026 13:00:00 GMT</pubDate>
<description>POTOMAC, MD / ACCESS Newswire / March 18, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced it will demonstrate its Agentic ...</description>
</item>
<item>
<title>IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research</title>
<link>https://6ix.com/company/igc-pharma-inc/news/igc-pharma-files-utility-patent-applications-covering-ai-based-data-harmonization-architecture-supporting-alzheimers-research</link>
<guid isPermaLink="true">https://6ix.com/company/igc-pharma-inc/news/igc-pharma-files-utility-patent-applications-covering-ai-based-data-harmonization-architecture-supporting-alzheimers-research</guid>
<pubDate>Thu, 26 Feb 2026 13:30:00 GMT</pubDate>
<description>POTOMAC, MD / ACCESS Newswire / February 26, 2026 /IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced the filing of utility patent ...</description>
</item>
<item>
<title>IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets</title>
<link>https://6ix.com/company/igc-pharma-inc/news/igc-pharma-notes-updated-research-coverage-from-ascendiant-capital-markets</link>
<guid isPermaLink="true">https://6ix.com/company/igc-pharma-inc/news/igc-pharma-notes-updated-research-coverage-from-ascendiant-capital-markets</guid>
<pubDate>Tue, 24 Feb 2026 13:30:00 GMT</pubDate>
<description>POTOMAC, MARYLAND / ACCESS Newswire / February 24, 2026 /IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that Ascendiant Capital Markets has issued an updated equity research report covering the Company. According to ...</description>
</item>
<item>
<title>IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial</title>
<link>https://6ix.com/company/igc-pharma-inc/news/igc-pharma-adds-visionary-investigators-network-as-clinical-site-to-phase-2-calma-trial</link>
<guid isPermaLink="true">https://6ix.com/company/igc-pharma-inc/news/igc-pharma-adds-visionary-investigators-network-as-clinical-site-to-phase-2-calma-trial</guid>
<pubDate>Mon, 23 Feb 2026 13:30:00 GMT</pubDate>
<description>- Practice integrated neurology network expands enrollment capacity - POTOMAC, MARYLAND / ACCESS Newswire / February 23, 2026 /IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced the addition of Visionary Investigators Network ...</description>
</item>
<item>
<title>IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances</title>
<link>https://6ix.com/company/igc-pharma-inc/news/igc-pharma-secures-north-american-composition-protection-for-igc-ad1-as-phase-2-calma-enrollment-advances</link>
<guid isPermaLink="true">https://6ix.com/company/igc-pharma-inc/news/igc-pharma-secures-north-american-composition-protection-for-igc-ad1-as-phase-2-calma-enrollment-advances</guid>
<pubDate>Tue, 17 Feb 2026 13:30:00 GMT</pubDate>
<description>POTOMAC, MD / ACCESS Newswire / February 17, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that the Canadian Intellectual Property Office ("CIPO") has issued a Notice of Allowance covering the proprietary composition ...</description>
</item>
<item>
<title>IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets</title>
<link>https://6ix.com/company/igc-pharma-inc/news/igc-pharma-to-participate-in-fireside-chat-with-ascendiant-capital-markets</link>
<guid isPermaLink="true">https://6ix.com/company/igc-pharma-inc/news/igc-pharma-to-participate-in-fireside-chat-with-ascendiant-capital-markets</guid>
<pubDate>Thu, 12 Feb 2026 13:30:00 GMT</pubDate>
<description>POTOMAC, MD / ACCESS Newswire / February 12, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital ...</description>
</item>
<item>
<title>IGC Pharma Announces Equity Research Update by Alliance Global Partners</title>
<link>https://6ix.com/company/igc-pharma-inc/news/igc-pharma-announces-equity-research-update-by-alliance-global-partners</link>
<guid isPermaLink="true">https://6ix.com/company/igc-pharma-inc/news/igc-pharma-announces-equity-research-update-by-alliance-global-partners</guid>
<pubDate>Tue, 10 Feb 2026 13:30:00 GMT</pubDate>
<description>POTOMAC, MARYLAND / ACCESS Newswire / February 10, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that Alliance Global Partners ("AGP") has published an updated equity research report covering the Company. The ...</description>
</item>
<item>
<title>IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center</title>
<link>https://6ix.com/company/igc-pharma-inc/news/igc-pharma-expands-phase-2-calma-trial-into-colombias-premier-alzheimers-research-center</link>
<guid isPermaLink="true">https://6ix.com/company/igc-pharma-inc/news/igc-pharma-expands-phase-2-calma-trial-into-colombias-premier-alzheimers-research-center</guid>
<pubDate>Mon, 09 Feb 2026 13:30:00 GMT</pubDate>
<description>- Adds world renowned GNA site to broaden genetic diversity and strengthen path toward 2026 data catalyst - POTOMAC, MARYLAND / ACCESS Newswire / February 9, 2026 /IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced the expansion ...</description>
</item>
<item>
<title>IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation</title>
<link>https://6ix.com/company/igc-pharma-inc/news/igc-pharma-reaches-70percent-enrollment-in-phase-2-calma-trial-evaluating-igc-ad1-for-alzheimers-agitation</link>
<guid isPermaLink="true">https://6ix.com/company/igc-pharma-inc/news/igc-pharma-reaches-70percent-enrollment-in-phase-2-calma-trial-evaluating-igc-ad1-for-alzheimers-agitation</guid>
<pubDate>Mon, 02 Feb 2026 13:30:00 GMT</pubDate>
<description>POTOMAC, MARYLAND / ACCESS Newswire / February 2, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today reported it has reached approximately 70% of planned patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 ...</description>
</item>
<item>
<title>IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York</title>
<link>https://6ix.com/company/igc-pharma-inc/news/igc-pharma-expands-phase-2-calma-trial-with-new-clinical-trial-site-at-integrative-clinical-trials-in-new-york</link>
<guid isPermaLink="true">https://6ix.com/company/igc-pharma-inc/news/igc-pharma-expands-phase-2-calma-trial-with-new-clinical-trial-site-at-integrative-clinical-trials-in-new-york</guid>
<pubDate>Thu, 22 Jan 2026 14:00:00 GMT</pubDate>
<description>- Multi-Specialty CNS Research Center Strengthens Trial Execution and Patient Diversity in Alzheimer's Agitation Study - POTOMAC, MD / ACCESS Newswire / January 22, 2026 /IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage ...</description>
</item>
<item>
<title>IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia</title>
<link>https://6ix.com/company/igc-pharma-inc/news/igc-pharma-expands-phase-2-calma-trial-with-new-clinical-site-at-dominion-medical-associates-a-lightship-network-site-in-richmond-virginia</link>
<guid isPermaLink="true">https://6ix.com/company/igc-pharma-inc/news/igc-pharma-expands-phase-2-calma-trial-with-new-clinical-site-at-dominion-medical-associates-a-lightship-network-site-in-richmond-virginia</guid>
<pubDate>Mon, 12 Jan 2026 14:00:00 GMT</pubDate>
<description>- Hybrid Trial Model Enhances Participant Access, Retention, and Enrollment Efficiency Across Underserved and Rural Communities - POTOMAC, MD / ACCESS Newswire / January 12, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage ...</description>
</item>
<item>
<title>IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability</title>
<link>https://6ix.com/company/igc-pharma-inc/news/igc-pharma-aligns-fiscal-year-with-calendar-year-to-enhance-us-investor-transparency-and-comparability</link>
<guid isPermaLink="true">https://6ix.com/company/igc-pharma-inc/news/igc-pharma-aligns-fiscal-year-with-calendar-year-to-enhance-us-investor-transparency-and-comparability</guid>
<pubDate>Tue, 06 Jan 2026 13:00:00 GMT</pubDate>
<description>POTOMAC, MD / ACCESS Newswire / January 6, 2026 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's ...</description>
</item>
</channel>
</rss>